Synbiotic formulation demonstrates dual therapeutic effect on gastrointestinal symptoms and anxiousness

Key Highlights

• BK002 achieved an 83% responder rate.
• A significant alleviation of gastrointestinal symptoms in IBS patients.
• A significant reduction in anxiousness.

BiOkuris announced positive topline results from its pivotal clinical study, Vitabiotic, evaluating BK002, the company’s synbiotic formulation for the treatment of Irritable Bowel Syndrome (IBS).

The multi-center, double-blind, randomized controlled trial met all its clinical endpoints, with a 83% responder rate, BK002 also showed a dual effect: significant relief of gastrointestinal symptoms and meaningful reduction in anxiousness. These findings highlight the importance of targeting the gut–brain axis in IBS.

“BK002 offers a unique dual benefit—relieving gastrointestinal symptoms while reducing anxiousness,” said François Blondel, CEO of BiOkuris. “These results validate our technology and demonstrate a new approach to IBS treatment that addresses both physical and psychological aspects of the disease.”

Benoit Palms, Chief Business Officer, added: “The Vitabiotic study provides strong clinical validation for BK002. The very high responder rate and its dual effect distinguishes it from existing therapies, and we are now actively seeking strategic partners to bring this innovative product to market in 2026.”

BK002 is a patented synbiotic combination of fungal chitin-glucan, the probiotic strain Lactobacillus acidophilus NCFM®, and vitamin D3. This multi-component formulation targets gastrointestinal function while engaging the gut–brain axis, offering a comprehensive approach to IBS management. PRESS RELEASE

IBS affects an estimated 10–20% of the global population, yet more than 60% of patients remain dissatisfied with current treatment options. BK002 addresses this unmet need through its multi-component mechanism, supporting gut function, reinforcing the intestinal barrier, and improving psychological well-being.